



(51) International Patent Classification:

C12N 5/0784 (2010.01) A61K 48/00 (2006.01)
A61K 35/15 (2015.01)

(21) International Application Number:

PCT/EP2022/063606

(22) International Filing Date:

19 May 2022 (19.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

21174802.5 19 May 2021 (19.05.2021) EP
22158117.6 23 February 2022 (23.02.2022) EP

(71) Applicant: ASGARD THERAPEUTICS AB [SE/SE];
Medicon Village, 223 81 Lund (SE).

(72) Inventors: FIÚZA ROSA, Fábio; Rua do Brejo, No53
Touria Pousos, 2410-205 Leiria (PT). ZIMMERMANN-
VA, Olga; Nad Cihelnou 666, 58291 Svetla Nad Saza-
vou (CZ). BARROS FERREIRA, Alexandra Gabriela;
Largo 12 de Dezembro N° 24, 1°C 4705-259 Lomar-Braga
(PT). ASCIC, Ervin; Dieseltasse 1/1/8, 1100 Vienna (AT).
FERREIRA PIRES, Cristiana; Rua Fomento do Azeiteiro n29,
3770-352 Palhaça (PT). RIBEIRO LEMOS PEREIRA,

Carlos Filipe; Rua João Batista da Silva nº390, Moledo,
4910-264 Caminha (PT).

(74) Agent: HØIBERG P/S; Adelgade 12, 1304 Copenhagen K
(DK).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: REPROGRAMMING OF CELLS TO TYPE 1 CONVENTIONAL DENDRITIC CELLS OR ANTIGEN-PRESENTING CELLS




Fig. 1

(57) Abstract: The present invention relates to compositions comprising transcription factors under control of promoter regions, wherein said compositions can be used for reprogramming cells to type 1 conventional dendritic cells or antigen-presenting cells. The invention further relates to methods for reprogramming cells into type 1 conventional dendritic cells or antigen-presenting cells.

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*